Hepatitis b Virus Clinical Trial
Official title:
The Efficacy of HBV Vaccine Response and Prevalence of Occult HBV Infection in Isolated Anti HBc Between HIV Infected and HIV Un-infected Thai Patients
The prevalence of Hepatitis B core antigen in the Thai population is about 70 %, no data of isolated Hepatitis B core antigen is reported. Hepatitis B core antigen is observed in 10%-20% of individuals from low endemic areas of HBV infection. However, this prevalence of isolated antiHBc would be higher in endemic area of HBV infection. There is conflicting data of occult HBV infection in HIV infected patients. In Thailand, perinatal transmission is the main route of transmission which is different from developed countries. Therefore, isolated antiHBc in Thai people has longer duration than low prevalence regions. Moreover, HBV genotype C and B is common in this region. If the HBV vaccination could eliminate an occult HBV infection in these individuals, the liver related mortality might be reduced. The prevalence and clinical importance of isolated antiHBc in Thai have not been investigated yet. There is also limited data of HBV vaccine response in this setting.
The prevalence of the Hepatitis B core antigen (anti-HBc)in the Thai population is about 70
%. No data of isolated anti-HBc is reported. Anti-HBc antigen is observed in 10%-20% of
individuals from low endemic areas of HBV infection. The prevalence of isolated antiHBc
antigen is expected to be higher in endemic areas of HBV infection. There is conflicting data
of occult HBV infection in HIV-infected patients. In Thailand, perinatal transmission is the
main route of HBV transmission, different from developed countries. Therefore, isolated
anti-HBc in Thai people has longer duration than low prevalence regions. Moreover, HBV
genotype C and B is common in this region. HBV genotype C is correlated with more cirrhosis
and hepatoma than genotype B. A study from Taiwan demonstrated that HBV DNA > 100,000
copies/ml is correlated with cirrhosis and hepatoma. Sustained reduction of HBV replication
lowers the risk of hepatoma in HBV related cirrhosis. If the HBV vaccination could eliminate
an occult HBV infection in these individuals, the liver related mortality will be reduced.
The prevalence and its clinical importance of isolated anti-HBc in the Thai population has
not been investigated yet. There is also limited data of HBV vaccine response in this
setting.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03459521 -
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
|
N/A | |
| Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
| Completed |
NCT00912847 -
Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT04072211 -
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
|
Phase 4 | |
| Completed |
NCT01204762 -
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
|
Phase 2 | |
| Completed |
NCT00805675 -
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
|
Phase 3 | |
| Completed |
NCT02785835 -
Hepatocellular Carcinoma in HIV-infected Patients
|
||
| Completed |
NCT03083821 -
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
|
Phase 1 | |
| Recruiting |
NCT01083251 -
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
|
N/A | |
| Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|
||
| Recruiting |
NCT04231565 -
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
|
N/A | |
| Terminated |
NCT00678587 -
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
|
Phase 3 | |
| Completed |
NCT00739752 -
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
|
N/A | |
| Completed |
NCT03294798 -
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04385524 -
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
|
N/A | |
| Enrolling by invitation |
NCT00663182 -
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
|
Phase 4 | |
| Completed |
NCT00769730 -
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
|
N/A | |
| Completed |
NCT01438424 -
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
|
Phase 2 | |
| Withdrawn |
NCT04046107 -
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT05406089 -
Effects of Antiviral Therapy on Patients With HBV-related HCC
|